Tumgik
#viral vector
bpod-bpod · 6 months
Text
Tumblr media
Accessing Opioids
Viral vector system to highlight and manipulate opioid receptors in the central and peripheral nervous systems brings greater understanding of opioid neurobiology and insight for gene therapy for disorders like pain and addiction
Read the published research paper here
Image from work by Gregory J. Salimando and colleagues
Dept. of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)
Published in Nature Communications, September 2023
You can also follow BPoD on Instagram, Twitter and Facebook
11 notes · View notes
esglatestmarketnews · 10 months
Text
Viral Vector—Perusal on Adeno-associated Viruses (AAVs) in Gene Therapy Development
The medical industry expects viral vectors to grow in prominence in transferring genetic material into the genetic composition of cells. Adeno-associated Viruses (AAVs) have become sought-after in gene therapy as they can deliver genetic material to cells and do not cause disease. Predominantly, adenovirus, retrovirus, herpes simplex virus and lentivirus, among others, are used to transfer genetic material into cells’ genetic composition. Technological advancements in manufacturing AAV vectors have encouraged stakeholders to boost their portfolios. An uptick in research activities in viral vector-based cell and gene therapies has redefined the global landscape. For instance, in 2020, over 100 gene-therapy products were observed in clinical trials.
Pharma companies, investors, venture capitalists and other stakeholders will possibly explore the growth potential in viral vectors. The final report, along with the database, will deep-dive into the following industry dynamics:
• AAV vectors approved by governing bodies, including FDA and the European Medicines Agency. Zolgensma was approved by EMA and FDA in 2020 and 2019, respectively, while Luxturna received the green signal from FDA in 2017 and EMA in 2018. 
• Insights on potential challenges for AAV manufacturers, such as cost, degradation during supply chain and preparation of stable viral vectors.
• Influence of the COVID-19 pandemic on vaccine development.
• Acquisitions of biotech startups
Get your copy or request a free sample of the report “Viral Vector Development - Focus on Adeno-associated Virus, 2018 – 2021,” compiled and published by Grand View Research.
Viral Vector Report Scope
Attribute
Details
Market Lineage
% Captured by AAV within Viral Vectors
Understanding of the parent market and ancillary industries
Plasmid DNA Contract Manufacturing
Cell & Gene Therapy Clinical Trials Market
Industry Dynamics
Viral Vector based gene therapy development
AAV Development workflow
Pipeline for AAV
Capitalist funding in the industry
Development Process
Deep dive Analysis
Understanding of AAV v/s Lentiviral v/s other viral vectors
Cost of manufacturing (based on batch size) - a case study
Case study on setting up a development plant
Competition Analysis in CDMOs
Companies with products in clinical trials
Various bioreactors used for development
Strategic initiatives undertaken in the last 5 years
Observation and Recommendations
This section will summarize the entire study and provide analyst insights with regards to key methods of development, technological advancements, and competitive profiling
Get more insights from our in-depth market intelligence report “Viral Vector Market Size, Share & Trends Analysis Report By Vector Type (Adeno-associated Virus (AAV), Adenovirus, Lentivirus, Retrovirus, Others), By Application, By End-user, By Region, And Segment Forecasts, 2023 – 2030”
About Us
Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.
Find More information @ https://www.grandviewresearch.com/info/trend-reports
0 notes
root-analysis · 1 year
Text
Viral Vector Manufacturing | Gene Therapy Manufacturing | Market (2035)
The Roots Analysis report features an extensive study of the rapidly growing demand for the adeno-associated viral vector manufacturing market, focusing on contract manufacturers. The gene therapy market is to be worth more than USD 2 Billion by 2035 at an Annualized Rate of Over 20%. One of the key objectives of this report was to evaluate the current market size and future opportunities. Get the detailed analysis report now!
Tumblr media
0 notes
designershop · 3 months
Text
CROCODILE COLLECTION🐊❤️
Check my redbubble⤵️❤️
Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media
2 notes · View notes
uniquegfx5u · 4 months
Text
Tumblr media
A Beautiful Girl Sketching Vector Portrait
Drawing is the only thing I've found in which I can lose myself completely. I love it. It started as something that relaxed me, but now it's a struggle because I'm pushing myself. The day-to-day sketching is fraught. Peter Capaldi
6 notes · View notes
princessnijireiki · 1 year
Text
anyway our CNS & brains are pretty complex, like we've barely figured out getting people with partial spinal cord damage back driving their own bodies + when we do it's still a roll of the dice & the processes are not all well understood... encephalitis can caused locked-in-ness like with sleeping sicknesses, akinetic mutism, etc where the body itself is not physically incapable of movement & action, but nothing is out there that jumps in and takes over from a driver who's paralyzed or asleep at the wheel... that's not actually a thing, it's fun speculative fiction but not representative of reality— so really, no worries lol
9 notes · View notes
serenesirene · 1 year
Text
I might go to the party tonight after all- Dr. H won't be there, so...
2 notes · View notes
thelegend9798 · 2 years
Text
The Biochemistry of Gene Therapy
The Biochemistry of Gene Therapy
Introduction Delivery Systems for Gene Therapy Viral Vectors Non-Viral Vectors A New Era of Gene Therapy References Gene therapy is a therapeutic technique designed to correct or reduce the symptoms of a particular disease. This is achieved by transferring an exogenous, wild-type gene into the target cells of an individual. The wild-type gene can act to replace, modify or block the defective…
Tumblr media
View On WordPress
3 notes · View notes
Text
Viral Vector Manufacturing Market Trends and Opportunities, Forecast by 2030
Tumblr media
The latest “ Viral Vector Manufacturing Market Forecast | Share and Size - 2030” report by The Insight Partners offers a detailed analysis of prime factors that impact the market growth such as key market players, current market developments, and pivotal trends. The report includes an in-depth study of key determinants of the global market including drivers, challenges, restraints, and upcoming opportunities.
This market report is ideal for businesses opting to enter or excel in the Viral Vector Manufacturing market. This strategic market forecast not only makes businesses aware of present market scenarios but also presents future market forecasts. These insights profoundly cover Viral Vector Manufacturing market size, share, growth, and projected revenue in the forecast duration.
The Viral Vector Manufacturing market report encompasses driving factors of the market coupled with prime obstacles and restraining factors that hamper the Viral Vector Manufacturing market growth. The report helps existing manufacturers and entry-level companies devise strategies to battle challenges and leverage lucrative opportunities to gain a foothold in the global market.
How is the Viral Vector Manufacturing Market Report Beneficial for Your Business?
Figure out the Viral Vector Manufacturing market dynamics altogether | 2030
Inspect and scrutinize the competitive scenario and the future Viral Vector Manufacturing market landscape with the help of different strictures including Porter's five forces.
Understand the impact of different government regulations throughout the global Viral Vector Manufacturing market and evaluate the market condition in the tough time.
Consider the portfolios of the protruding players functional in the market in consort with the thorough study of their products/services.
Have a compact idea of the highest revenue-generating segment with the help of a thorough Viral Vector Manufacturing market analysis by our seasoned research experts.
A cost-effective way to gain valuable insights into the Viral Vector Manufacturing market without the need to host an independent team of researchers at their own cost.
Viral Vector Manufacturing Market diagrams, pie charts, regional market share maps, inventory network examination, and import/trade subtleties help you pitch investors.
The Viral Vector Manufacturing market report offers an in-depth analysis of the various prime market players that are active in the market. Moreover, it provides their thorough financial analysis, business strategies, SWOT profile, business overview, and recently launched products & services. In addition, the report offers recent market developments such as market expansion, mergers & acquisitions, and partnerships & collaborations. The prime market players observed in the report are Companies Charles River Laboratories, Merck KGaA, Biovian Oy, Global Life Sciences Solutions USA LLC, Lonza Group Ltd, Creative Biogene, VIVEbiotech SL, Genezen Laboratories Inc, GenScript Biotech Corporation, AGC Biologics and othersOn the Basis of Type this market is categorized further into-
Adenoviral Vectors
Adeno-Associated Viral Vectors
Lentiviral Vectors
Retroviral Vectors
and Others
On the Basis of Disease Indication this market is categorized further into-
Cancer
Genetic Disorders
Infectious Disease
and Others
On the Basis of Application this market is categorized further into-
Therapeutics Development
Vaccine Development
and CDMOs & CROs
On the Basis of End User this market is categorized further into-
Pharmaceutical and Biotechnology Companies
Research Institutes
and Others
The report offers an in-depth study of every segment, which helps market players and stakeholders understand the fastest-growing segments with maximum Viral Vector Manufacturing market share and highest-grossing segments in the market.
The Viral Vector Manufacturing market is analyzed across the globe and highlights several factors that affect the performance of the market across the key regions –
North America (U.S., Canada, Mexico)
Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
Latin America (Brazil, Rest of Latin America)
The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)
Rest of the World
The Viral Vector Manufacturing market research offers revenue forecasts for every year coupled with sales growth of the market. The forecasts are provided by skilled analysts and after an in-depth analysis of the Viral Vector Manufacturing market trends. These forecasts are essential for gaining investment insights into the prospects of any industry.About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.
0 notes
Text
Viral Vector And Plasmid DNA Manufacturing Market To Reach $19.5 Billion By 2030
Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends
Tumblr media
The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.
With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.
Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.
Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.
Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market
Viral Vector And Plasmid DNA Manufacturing Market Report Highlights
Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
Viral Vector and Plasmid DNA Manufacturing Market Segmentation
Grand View Research has segmented the global viral vector and plasmid DNA manufacturing market based on the vector type, workflow, application, end-use, disease, and region:
Viral Vector and Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Billion, 2018 - 2030)
Adenovirus
Retrovirus
Adeno-Associated Virus (AAV)
Lentivirus
Plasmids
Others
Viral Vector and Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Billion, 2018 - 2030)
Upstream Manufacturing
Vector Amplification & Expansion
Vector Recovery/Harvesting
Downstream Manufacturing
Purification
Fill Finish
Viral Vector and Plasmid DNA Manufacturing Application Outlook (Revenue, USD Billion, 2018 - 2030)
Antisense & RNAi Therapy
Gene Therapy
Cell Therapy
Vaccinology
Research Applications
Viral Vector and Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Pharmaceutical and Biopharmaceutical Companies
Research Institutes
Viral Vector and Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Billion, 2018 - 2030)
Cancer
Genetic Disorders
Infectious Diseases
Others
Viral Vector and Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Viral Vector and Plasmid DNA Manufacturing Market
Merck KGaA
Lonza
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Cobra Biologics
Catalent Inc.
Wuxi Biologics
Takara Bio Inc.
Waisman Biomanufacturing
Genezen laboratories
Batavia Biosciences
Miltenyi Biotec GmbH
SIRION Biotech GmbH
Virovek Incorporation
BioNTech IMFS GmbH
Audentes Therapeutics
BioMarin Pharmaceutical
RegenxBio, Inc.
Browse Full Report: https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market
0 notes
pharmanucleus1 · 3 months
Text
Viral Vector Gene Delivery Market: Advancements, Opportunities, and Future Trends
Market Overview 
Viral vector is the most sought-after way to transfer genes to specific cell types or tissues and manipulate them to express therapeutic genes. Currently, there are several types of viruses, such as adenovirus, adeno associated virus, baculovirus and retrovirus, which are being investigated in order to deliver the genes to required cells. This process can provide permanent as well as transient transgene expression.
Market Dynamics 
Viral vectors are primarily used in the development of various gene therapies and are showing great promise in disease landscape. Moreover, during the unprecedented times of COVID-19, the development of adenovirus-vector vaccine has helped to mitigate the dangerous risks associated with the pandemic.? 
Since the viral vector-based gene therapies have shown promising results in the past, the developers are exploring its full potential to reach to its long-term success. With the ongoing rise in demand, the service providers are continuously expanding their facilities to meet the numbers. In August 2022, Thermofischer has expanded its cell and gene therapy capability by opening the new viral vector manufacturing facility in Massachusetts, US. 
In June 2022, VIVEbiotech has completed the acquisition of its lentiviral vector manufacturing capabilities to support the customers throughout the development cycle. 
In June 2022, Avid Bioservices expanded its viral vector focused facility with 53,000 sq. ft. area to address the demand of viral vector production at commercial scale. 
The increasing prevalence of various genetic disorders and target diseases increased funding availability for development of gene therapy, research efforts in the field of viral vector-based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market. 
Click here for full report:
Challenges 
The ongoing challenge, which is linked with its ability to pass the immune system and high number of doses are some of the limiting factors delaying the success of such therapies. Further, the quality of transgene expression plays another crucial role for the desired clinical effect. The combinatorial factors demand innovations at the R&D scale, which will gain traction in investment from various organizations. 
In June 2022, NSW Government of Australia allocated USD 101.4 million to the commercial facility of viral vector manufacturing. This clearly indicates the need to improve the viral vector-based therapy due to its significant potential to cure multiple indications.?? 
Development Landscape: 
Biotech and pharmaceutical businesses are adopting both organic and inorganic growth strategies to advance their pipeline and gain competitive edge in the market over the peers. 
In April 2022, ProteoNic and NecstGen announced a collaboration, wherein the respective players will utilize their proprietary platforms to advance the AAV and LV viral vector manufacturing technology. 
Till now, only eight viral vector-based gene therapies have been approved by the US FDA, which were developed using three viral vectors- adeno associated virus, lentivirus and herpes simplex virus. 
As of September 2022, over 145 clinical trial studies are going on with over 10,000 patients worldwide. The exploratory pipeline of viral vector-based therapy continues to grow across the indications and targets with promising results. 
Click here for free sample report:
Key players: 
Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US) 
Click here for full report:
https://www.pharmanucleus.com/reports/viral-vector-gene-delivery
Upcoming players: 
TBD 
Regional Analysis: 
North America?is anticipated to capture the highest share of this market over the forecast period (2022-2027), with U.S. accounting for the maximum contribution. Presence of most number of manufacturing facilities and key players, some of the best research universities and an encouraging start-up eco system provides an ideal environment for research leading to more successful assets in pipeline. Macro-economic factors such as large population and growing economy, high prevalence of cancer and infectious diseases, better access to insurance, availability of crowd funding and support from various stakeholders’ fuels US as a commercially attractible market. 
In 2019, the New Jersey Innovation Institute signed an agreement with Pall Corporation to develop a BioPharmaceutical Innovation iLab to help fix the viral vector shortage using continuous manufacturing. 
Thermo Fisher Scientific opened a cGMP manufacturing facility in Plainville, US which helped double the company’s commercial viral vector capacity?and?meet rising demand for the development and manufacturing of gene therapies and vaccines. 
Europe?also remains a favourable region on par with the North American region. Presence of highly skilled researchers, well-developed R&D ecosystem, support from government agencies and regulatory bodies are the major driving factors in Europe. 
In 2021, Yposkesi announced that its bioproduction project has been selected for the French government’s “Plan de Relance” initiative, which is an economic stimulus package aimed at making the nation’s bioproduction industry strategically more robust and economically resilient is investing USD6 million in its “Boost” project to develop a new generation 1000-L, GMP platform with optimized manufacturing and control processes for efficient viral vector production from the thawing of cells up to the aseptic filling of the end product. 
Asia-Pacific?region is expected to pick up pace over the next few years due to favourable regulatory climate, increasing investments to drive market access in key markets such as Japan, China, Australia, Singapore and India. The market is focusing on Asia-Pacific as a destination for outsourcing and trying to gain foothold through mergers, collaborations, and strategic acquisitions. 
In 2022, National Cancer Center Japan and GenScript ProBio entered into research collaboration agreement for a plasmid and lentiviral vector CMC development to develop plasmid and lentiviral vector for cell therapy to aim on FDA acceptance of IND applications. 
In 2022, VectorBuilder, a CDMO announced an investment of USD 500m for China viral vector plant. The campus will include 30 production suites designed to manufacture lentivirus, plasmids, messenger RNA (mRNA), adeno-associated virus (AAV), cell lines and other types of viral and non-viral vectors. 
0 notes
hebasoffar · 3 months
Video
youtube
(via Top Trends on Eilik and vector robots, Who is the best? - Science online)
0 notes
asteamtechnosolutions · 3 months
Text
Types of AC Drive
Tumblr media
VFD
Multi-level Drive
Regenerative Drive
Vector Drive
Servo Drive
🌐Website :- https://asteamtechno.com
👉Contact us :- +91 95372 40404
📧Email :- [email protected]
1 note · View note
aditya-takavade21 · 6 months
Text
0 notes
smritifw · 9 months
Text
0 notes
onccoancaonisancapi · 10 months
Text
0 notes